Edwards Lifesciences (EW) to Release Earnings on Wednesday

Edwards Lifesciences (NYSE:EW) is expected to be announcing its earnings results after the market closes on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.60 per share and revenue of $1.40 billion for the quarter. Edwards Lifesciences has set its FY 2025 guidance at 2.400-2.500 EPS and its Q1 2025 guidance at 0.580-0.640 EPS.Parties that wish to register for the company’s conference call can do so using this link.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Trading Up 0.5 %

Shares of Edwards Lifesciences stock opened at $71.56 on Monday. The firm has a 50-day simple moving average of $71.31 and a two-hundred day simple moving average of $70.92. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a market cap of $42.07 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $78.55.

Insider Activity

In related news, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company’s stock, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Edwards Lifesciences stock. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,587 shares of the medical research company’s stock, valued at approximately $266,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.